Overall verdict
Neutral
6.4/10
1-year performance
-5.32%
Score breakdown
Down 5.3% over 1 year, 35% of the 52-week range.
Strongest: Financial strength 10.0/10. Weakest: Valuation 2.3/10.
33 analysts, target +0.1% vs the price.
Intuitive Surgical, Inc. develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. It offers the da Vinci Surgical System that enables surgical procedures using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic endoluminal procedures enabling minimally invasive biopsies in the lung.
The company also provides a suite of stapling, energy, and core instrumentation for its multi-port da Vinci surgical systems ; progressive learning pathways to support the use of its technology ; infrastructure of customer service and support specialists, a complement of services to its customers, including installation, repair, maintenance, 24/7 technical support, and proactive system health monitoring ;
and integrated digital capabilities providing connected offerings, streamlining performance for hospitals with program-enhancing insights. It sells its products through direct sales organizations, such as capital and clinical sales teams. Intuitive Surgical, Inc. was incorporated in 1995 and is headquartered in Sunnyvale, California.
Sector
Health Care
Industry
Health Care Equipment and Supplies
Primary listing
Nasdaq
United States
CEO
David Rosa
Founded
1995
Employees
17 021
Revenue / employee
591 311 USD
Next earnings
October 20, 2026
Institutional holders
- BlackRock, Inc.8.50%
- VANGUARD CAPITAL MANAGEMENT LLC6.55%
- STATE STREET CORP4.55%
- Invesco Ltd.3.35%
- PRICE T ROWE ASSOCIATES INC /MD/3.19%
- GEODE CAPITAL MANAGEMENT, LLC2.42%
- Capital World Investors2.19%
- VANGUARD PORTFOLIO MANAGEMENT LLC2.05%
- MORGAN STANLEY1.86%
- Other institutions51.75%
- Rest of the register13.61%
2244 13F filings as of June 30, 2026: US managers above $100M, filed up to 45 days after quarter end. No insiders, no retail. A share on loan is declared by its lender and by whoever bought it from the short seller, so the total can exceed 100%.
Research uses the underlying stock’s market history. The purchase quote is calculated separately when you review your order.
52-week high
603.88 USD
52-week low
328.57 USD
1-year performance
-5.32%
Declining
Year-to-date performance
-25.20%
Declining
Drawdown
-29.79%
Marked drawdown
Position in the 52-week range
35% of range
Against the world ETF
Over 17 years, from September 2009 to September 2026, the share did not clearly beat the world ETF once risk is accounted for. It earned more, but shaking 2.3 times harder: for the risk taken, the ETF paid better.
$10,000 placed at the end of September 2009 are worth today
| Intuitive Surgical | $139,549 |
| World ETF | $60,004 |
| S&P 500 | $97,541 |
| Risk-free placement | $12,831 |
The risk
- Shaking:the share moves 2.3 times as much as the world ETF.
- Worst fall:-50 % between November 2021 and October 2022. $10,000 placed at the top fell to $5,010. The world ETF, at worst: -34 %. Back to its high in 15 months.
Intuitive Surgical earned 2 times as much as the world ETF since 2009
Value of $10,000 placed at the end of September 2009, dividends reinvested, in dollars
- Intuitive Surgical: $139,549
- World ETF: $60,004
- S&P 500: $97,541
- Risk-free placement: $12,831
Based on past performance. This is not a recommendation.
Range: 198.95 USD - 204.95 USD (comparables only)
The price implies growth of 16.05% per year; the company grows at 21.79%.
Gross margin 66.7%, net margin 28.4%, ROIC 17.4%, ROE 17.4%.
Net margin
28.45%
Exceptional
Sector 8.34%|S&P 13.13%
Gross margin
66.66%
Fair
Return on equity (ROE)
17.43%
Exceptional
Sector 6.87%|S&P 16.52%
Return on invested capital (ROIC)
17.43%
Exceptional
Free cash flow margin (FCF)
29.21%
Exceptional
Profit-to-cash conversion (FCF conversion)
1.03x
High
Margin stability
3.3 pts
Steady
Revenue to net income
Growth
7.8/10Revenue up 18.5% over 1 year, 18.2% a year over 5, EPS 21.8% a year over 5.
Revenue (trailing 12 months)
11.0Md USD
Revenue growth (1y)
18.54%
Hyper-growth
Revenue growth (3y)
61.75%
Strong
EPS growth (1y)
26.62%
Hyper-growth
EPS CAGR (5y)
21.79%
Exceptional
EPS revisions (3 months)
3.66%
Revised up
Valuation
2.3/10P/E 48.6x, forward P/E 45.3x, EV/EBITDA 34.6x, PEG 2.23. The multiple sits in the 20th percentile of its own 5-year history.
P/E (TTM)
48.6x
Expensive
Sector 28.7x|S&P 23.5x
Forward P/E
45.3x
Very expensive
EV / EBITDA
34.6x
Very expensive
Sector 15.6x|S&P 14.7x
PEG
2.23
Very expensive
Sector 1.76|S&P 0.87
Fair value (reverse DCF)
201.95 USD
Deeply overvalued
P/E vs its own 5-year history
among the 20% lowest valuations
Far cheaper than usual
Market cap
150Md USD
Financial strength
10.0/10net debt/EBITDA -1.6x.
Net debt / EBITDA
-1.6x
Net cash
Gearing (net debt / equity)
-28.67%
Net cash
Cash
5.2Md USD
Cash / market cap
3.50%
Tight
Net debt
-5.2Md USD
Equity
18.3Md USD
Closed daily candles, 2 years
Last close on October 9, 2026: 423.96 USD
- MM20400.65
- MM50386.10
- MM200443.41
- RSI 1466.7
Top panel: closed candles, 20, 50 and 200-day moving averages, with volume in grey. Bottom panel: 14-day RSI with dashed 30 and 70 levels.
200-day average slope, 1 month
-3.78%
200-day average slope, 3 months
-9.10%
50-day average slope, 1 month
+2.11%
Price structure
higher-low
Bullish RSI divergence
No
20-day volatility
1.59 % per day
Volatility change
-33.85%
Forecasts by fiscal year
| Fiscal year | EPS | Normalised EPS | Revenue | EBITDA | Net income |
|---|---|---|---|---|---|
| 2026 | 9.36 (10) | 10.80 (27) | 11 755 (31) | 5 327 (11) | 3 303 (12) |
| 2027 | 10.65 (10) | 12.11 (27) | 13 261 (31) | 5 839 (11) | 3 776 (12) |
Amounts in millions of USD, EPS in USD per share. In brackets, the number of analysts. Consensus as of October 9, 2026.
Same sub-industry: 193 companies behind the medians.
| # | Company | Code | Country | Overall / 10 | Fundamentals / 10 | Mkt cap | P/E | Net margin | Revenue growth | ROIC | Net debt / EBITDA | FCF yield | 1-year perf. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | MDT | 7.0 | 7.1 | 113Md USD | 21.8x | 13.9 % | 13.7 % | 7.0 % | 2.0x | 5.4 % | -9.9 % | ||
| 2 | BSX | 6.9 | 7.3 | 61.9Md USD | 17.3x | 17.5 % | 7.5 % | 10.5 % | 1.8x | 5.9 % | -56.0 % | ||
| 3 | SYK | 6.8 | 7.5 | 106Md USD | 28.7x | 14.4 % | 9.4 % | 10.0 % | 1.7x | 4.4 % | -26.2 % | ||
| 4 | ABT | 6.7 | 6.3 | 172Md USD | 32.2x | 11.6 % | 13.0 % | 7.5 % | 0.5x | 4.5 % | -26.0 % | ||
| 5 | SHL | 6.5 | 6.5 | 49.0Md USD | 19.8x | 9.6 % | 1.8 % | 7.4 % | 2.7x | 5.2 % | -19.4 % | ||
| 6 | ISRG | 6.4 | 6.4 | 150Md USD | 48.6x | 28.4 % | 18.5 % | 17.4 % | -1.6x | 2.2 % | -5.3 % | ||
| 7 | EW | 6.3 | 5.6 | 49.1Md USD | 50.6x | 15.0 % | 13.6 % | 8.7 % | -2.0x | 2.9 % | 12.5 % | ||
| 8 | IDXX | 6.1 | 6.4 | 40.8Md USD | 36.4x | 25.0 % | 9.7 % | 56.6 % | 0.5x | 3.1 % | -17.1 % | ||
| 9 | BDX | 5.3 | 5.0 | 50.1Md USD | 55.4x | 6.2 % | 5.4 % | 3.2 % | 3.4x | 5.1 % | 20.4 % |
